Analyst picks & changes
By BC Staff | Oct 23, 2006 | 7:00 AM GMT
Analyst picks & changes
| Analyst picks & changes |
| Company | Bank | Analyst | Coverage | Opinion | Wk chg | 10/20 cls |
| Acorda (ACOR) | Banc of America Securities | David Witzke | Price target | Buy | 1% | $17.03 |
| Lazard | Joel Sendek | Price target | Buy | | |
| Witzke raised his target to $24 from $12 based on increased penetration assumptions for ACOR's Fampridine-SR in multiple sclerosis (MS) patients with walking disability. The sustained-release formulation of 4-aminopyridine (4-AP) met all three endpoints in a recent Phase III trial (see BioCentury, Oct. 2). |
| Sendek raised his target to $22 from $14, forecasting rapid approval and uptake of Fampridine-SR. He expects FDA approval in early 2009. |
| Aeterna Zentaris (TSX:AEZ; AEZS) | Dundee | David Martin | Price target | Market outperform | 6% | $5.36 |
| Martin lowered his target to $9 from $10 after the company sold 24% of its holdings in Atrium
|
Read the full 1331 word article
